Suppr超能文献

秘鲁基于方案和实验室的耐多药结核病治疗结果的一致性。

Concordance of programmatic and laboratory-based multidrug-resistant tuberculosis treatment outcomes in Peru.

机构信息

Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

出版信息

Int J Tuberc Lung Dis. 2012;16(3):364-9. doi: 10.5588/ijtld.11.0511.

Abstract

BACKGROUND

Confirmation of cure for multidrug-resistant tuberculosis (MDR-TB) patients requires laboratory tests for Mycobacterium tuberculosis growth on culture media. Outcome decisions dictate patient management, and inaccuracies place patients at an increased risk of morbidity and mortality, and may contribute to continued transmission of MDR-TB.

OBJECTIVE

To examine concordance between programmatic and laboratory-based MDR-TB treatment outcomes.

METHODS

The study population included 1658 MDR-TB patients in Peru treated between 1996 and 2002 with both program and laboratory-based outcomes. Laboratory-based outcomes were assigned according to international standards requiring at least five consecutive negative cultures in the last 12 months of treatment to confirm cure.

RESULTS

Compared to the global culture-defined standard classification, only 1.1% of treatment successes, but 54.3% of failures, were misclassified programmatically. Overall, 10.4% of patients identified by a clinician as having a successful treatment outcome still had cultures positive for MDR-TB.

CONCLUSION

Most patients with successful treatment outcomes by strict culture definitions were also classified by clinicians as having successful outcomes. However, many culture-confirmed failures were missed. In light of delays and incomplete access to culture in MDR-TB programs, efforts should be made to improve the accuracy of programmatically determined treatment outcomes.

摘要

背景

耐多药结核病(MDR-TB)患者的治愈确认需要在培养基上进行结核分枝杆菌生长的实验室检测。治疗结局决定了患者的管理方案,而检测结果不准确会使患者面临更高的发病率和死亡率风险,并可能导致 MDR-TB 的持续传播。

目的

研究基于方案和基于实验室的 MDR-TB 治疗结局之间的一致性。

方法

该研究人群包括 1996 年至 2002 年期间在秘鲁接受治疗的 1658 例 MDR-TB 患者,这些患者同时具有基于方案和基于实验室的治疗结局。基于实验室的治疗结局根据国际标准进行分配,要求在治疗的最后 12 个月内至少连续 5 次培养物阴性才能确认治愈。

结果

与全球基于培养物的标准分类相比,仅 1.1%的治疗成功病例被错误地归类为方案成功,而 54.3%的治疗失败病例被错误地归类为方案失败。总体而言,10.4%的临床医生认为治疗结局成功的患者,其培养物仍为 MDR-TB 阳性。

结论

根据严格的培养物定义,大多数治疗结局成功的患者也被临床医生归类为治疗成功。然而,许多经培养物确认的失败病例被遗漏了。鉴于 MDR-TB 项目中存在延迟和不完全获得培养物的情况,应努力提高方案确定的治疗结局的准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c94/4616001/376a4827d9e3/nihms729570f1.jpg

相似文献

本文引用的文献

6
Laboratory medicine in Africa: a barrier to effective health care.非洲的检验医学:有效医疗保健的障碍。
Clin Infect Dis. 2006 Feb 1;42(3):377-82. doi: 10.1086/499363. Epub 2005 Dec 20.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验